Innovative Multivalent Nanobody Fusion Targeting ALB and LTBR for Next-Generation Cancer Therapy

VHH-P587 is a humanized nanobody-based tetravalent Fc fusion protein designed to target both albumin (ALB) and lymphotoxin beta receptor (LTBR). This candidate integrates three single-domain antibodies against LTBR with an anti-serum albumin antibody, connected via a flexible 20GS linker, and is produced in a Pichia pastoris expression system. Currently in the biological testing phase, VHH-P587 is being developed for potential application in the treatment of cancer. By engaging both albumin and LTBR, VHH-P587 aims to leverage extended systemic half-life alongside specific immunomodulatory activity within the tumor microenvironment.

Licensing Opportunity

VHH-P587 is available for out-licensing to partners seeking innovative nanobody-based immuno-oncology assets. We invite discussions with biopharma organizations interested in advancing this program through collaborative development and commercialization.

Development Phase

Modality

VHH-P587 employs an advanced protein engineering strategy, combining three nanobody domains specific for LTBR with an anti-ALB nanobody, linked through a flexible 20GS peptide and fused to an Fc domain. This tetravalent architecture harnesses the unique advantages of single-domain antibodies, such as reduced molecular size and enhanced tissue penetration, essential for addressing tumor heterogeneity in cancer. The inclusion of an Fc region extends half-life and supports immune effector functions, while expression in Pichia pastoris offers scalable, cost-effective production. This modality promises improved tumor localization, stability, and manufacturability, presenting strong therapeutic potential for cancer intervention.

Target

ALB and LTBR are central to the design and function of VHH-P587. ALB, a predominant serum protein, plays a crucial role in molecule transport and maintenance of oncotic pressure; it is extensively expressed in the bloodstream and is leveraged as a carrier to prolong biologic half-life. LTBR, a receptor from the TNF receptor superfamily, is primarily found on certain immune and stromal cell subsets and is implicated in lymphoid tissue organization as well as tumor microenvironment modulation. As a cancer target, LTBR is of growing interest due to its role in immune cell infiltration and tumor stroma interaction. Strategically targeting ALB enables extended systemic exposure, while LTBR engagement directly modulates immunological pathways critical for anti-tumor responses. VHH-P587’s dual targeting of ALB and LTBR is thus positioned as a multipronged approach combining pharmacokinetic advantage with tumor microenvironment modulation.

Mechanism of Action

VHH-P587 operates through simultaneous engagement of ALB, extending its circulatory persistence, and LTBR, acting as an agonist to drive downstream immune activation. By binding ALB, VHH-P587 leverages the natural recycling of serum albumin, leading to prolonged systemic retention. Concurrently, the nanobody domains targeting LTBR mimic TNF family ligand activity, resulting in the activation of immune signaling pathways that can reprogram the tumor environment and promote anti-tumor immunity. The modular nanobody platform of VHH-P587 can be adapted for various therapeutic modalities, including antibody-drug conjugates and bispecific formats, offering versatility in cancer therapy design and future pipeline expansion.

Cancer

Cancer represents a group of disorders characterized by uncontrolled cell proliferation and the potential to invade or spread to distant tissues. As one of the leading causes of mortality globally, cancer poses a significant burden on healthcare systems with millions of new cases diagnosed annually worldwide. The current standard of care encompasses surgery, chemotherapy, radiotherapy, immunotherapy, and molecularly targeted interventions. While progress has been made, many patients experience limited efficacy, significant adverse events, or resistance to conventional therapies. There is an ongoing need for innovative treatments that provide durable responses, overcome immune evasion, and target the tumor microenvironment. The unique properties of VHH-P587 – combining extended serum half-life and LTBR-mediated immunomodulation – support its potential to fulfill unmet medical needs in cancer by enhancing therapeutic coverage and potentiating immune-mediated tumor eradication.